SUTRO BIOPHARMA, INC. Total Revenue

• SUTRO BIOPHARMA, INC. showed an increase of +65.2% in Total Revenue from 2024 to 2025.
• This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $14.85 million | Q2 2017: $15.36 million | Q3 2017: $17.50 million | Q4 2017: $4.04 million | Q1 2018: $5.79 million | Q1 2018: $5.79 million | Q2 2018: $5.70 million | Q2 2018: $5.70 million | Q3 2018: $7.84 million | Q3 2018: $7.84 million | Q4 2018: $19.09 million | Q1 2019: $8.63 million | Q2 2019: $10.53 million | Q3 2019: $12.28 million | Q4 2019: $11.31 million | Q1 2020: $7.15 million | Q2 2020: $9.47 million | Q3 2020: $17.82 million | Q4 2020: $8.28 million | Q1 2021: $14.66 million | Q2 2021: $28.05 million | Q3 2021: $8.52 million | Q1 2022: $5.90 million | Q2 2022: $28.10 million | Q3 2022: $25.15 million | Q1 2023: $12.67 million | Q2 2023: $10.41 million | Q3 2023: $16.92 million | Q1 2024: $13.01 million | Q2 2024: $25.71 million | Q3 2024: $8.52 million | Q1 2025: $17.40 million | Q2 2025: $63.75 million | Q3 2025: $9.69 million.
• Over the full 12 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Total Revenue has grown by 71.6%.
• Historical annual values: Fiscal year 2025: $102.48 million | Fiscal year 2024: $62.04 million | Fiscal year 2023: $153.73 million | Fiscal year 2022: $67.77 million | Fiscal year 2021: $61.88 million | Fiscal year 2020: $42.72 million | Fiscal year 2019: $42.74 million | Fiscal year 2018: $38.42 million | Fiscal year 2018: $38.42 million | Fiscal year 2017: $51.74 million | Fiscal year 2017: $51.74 million | Fiscal year 2016: $59.73 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026